Octagon Capital Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Octagon Capital Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,551,703	Closed	-$59.1M	–	47
2023 Q1	$59.1M	Hold	2,551,703	–	–	8.5%	2
2022 Q4	$66.9M	Hold	2,551,703	–	–	10.41%	2
2022 Q3	$50.2M	Hold	2,551,703	–	–	8.66%	3
2022 Q2	$44.6M	Buy	2,551,703 +1,195,453	+88%	+$18.8M	11.91%	3
2022 Q1	$22.2M	Buy	1,356,250 +856,250	+171%	+$11.6M	4.8%	7
2021 Q4	$8.15M	Buy	+500,000	New	+$7.12M	1.59%	15

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Octagon Capital Advisors's KDNY Position: Q2 2023 in Review

Octagon Capital Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 2,551,703 shares — an estimated $59.1M sold.

Octagon Capital Advisors first reported a position in KDNY in Q4 2021 and held it in 6 quarters. The position peaked at $66.9M in Q4 2022. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

Octagon Capital Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Octagon Capital Advisors sold 2,551,703 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $59.1M.
Octagon Capital Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Octagon Capital Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $66.9M in Q4 2022.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Octagon Capital Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.